- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
Withdrawn
Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
Cancer
Gastrointestinal tract
2 January 2024
Published on 04 Jan 2022
Last Updated on 02 Jan 2024
Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours Guidance is outdated and has been withdrawn on 2 Jan 2024.
The Plain English Summary (PES) has been updated on 2 Jan 2024.
Regorafenib and sunitinib for treating advanced GISTs (Withdrawn 2 Jan 2024) [PDF, 160 KB]
PES Regorafenib and sunitinib for advanced GISTs (Updated 2 Jan 2024) [PDF, 85 KB]